Seeking Alpha

Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports...

Salix Pharmaceuticals (SLXP) +8.4% premarket after saying that an FDA advisory panel supports its proposed trial to test repeat treatment cycles of its Xifaxan tablets for irritable bowel syndrome. (earlier)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector